SCHEMBL1748273

SCHEMBL1748273

CS(=O)(=O)c1nc2cc(F)ccc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.44
PTPN1 P18031 4/20 0.42
PTPN5 P54829 4/20 0.42
PTPN2 P17706 3/20 0.42
HSPD1 P10809 2/20 0.42
HSPE1 P61604 2/20 0.42
MPO P05164 1/20 0.40
GABRP O00591 3/20 0.39
GABRD O14764 3/20 0.39
GABRA1 P14867 3/20 0.39
GABRB1 P18505 3/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA5 P31644 3/20 0.39
GABRA3 P34903 3/20 0.39
GABRA2 P47869 3/20 0.39
GABRB2 P47870 3/20 0.39
GABRA4 P48169 3/20 0.39
GABRE P78334 3/20 0.39
GABRA6 Q16445 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31208321 1.00 FBP1 (0.44) FBP1PTPN1PTPN5PTPN2HSPD1
SCHEMBL1748264 0.87 MAPT (0.41) FBP1GABRPGABRDGABRA1GABRB1
SCHEMBL1748058 0.81 KDM4E (0.51) FBP1PTPN1PTPN5PTPN2ALDH1A1
SCHEMBL31208297 0.81 KDM4E (0.51) FBP1PTPN1PTPN5PTPN2ALDH1A1
SCHEMBL18613864 0.80 FBP1 (0.44) FBP1PTPN1PTPN5PTPN2HSPD1
SCHEMBL1748135 0.78 MAPT (0.51) ALDH1A1LMNAHTTPOLBL3MBTL1
SCHEMBL305334 0.75 LMNA (0.53) PTPN1PTPN5PTPN2ALDH1A1LMNA
SCHEMBL1747969 0.75 GAA (0.42) PTPN1PTPN5PTPN2CA2ALDH1A1
SCHEMBL1748015 0.74 SMN1; SMN2 (0.37) FBP1ALDH1A1F2RL3MAPTSMN1; SMN2
SCHEMBL30300530 0.73 L3MBTL1 (0.56) MPOGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409533-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-12-12 US disclosed
US-12071433-B2 HMOX1 inducers Astellas Engineered Small Molecules US, Incorporated (US) 2024-08-27 US disclosed
US-20240051952-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-02-15 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
EP-3952990-A1 HMOX1 INDUCERS Mitobridge, Inc. (US) 2022-02-16 EP disclosed
CN-113874074-A HMOX1 inducers 米托布里奇公司 2021-12-31 CN disclosed
WO-2020210339-A1 HMOX1 INDUCERS MITOBRIDGE, INC. (US) 2020-10-15 WO disclosed
US-10766888-B1 HMOX1 inducers MITOBRIDGE INC. (US) 2020-09-08 US disclosed
US-10766888-B1 HMOX1 inducers MITOBRIDGE INC. (US) 2020-09-08 US disclosed
US-20090270468-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity SMITH ROGER 2009-10-29 US disclosed
US-20090253762-A1 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY SMITH ROGER 2009-10-08 US disclosed
US-20090197795-A1 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER HEALTHCARE LLC (US) 2009-08-06 US disclosed
US-7423156-B2 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2008-09-09 US disclosed
US-20060194859-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2006-08-31 US disclosed
US-7091228-B2 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2006-08-15 US disclosed
CN-1816531-A Process for the preparation of aryl alkyl acid derivatives and their use for the treatment of obesity BAYER PHARMACEUTICALS CORP (US) 2006-08-09 CN disclosed
EP-1633722-A2 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY Bayer Pharmaceuticals Corporation (US) 2006-03-15 EP disclosed
WO-2004100881-A2 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2004-11-25 WO disclosed
US-20040224997-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224997-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity FABP4, GPR119, LIPC FBP1 1708/4885PTPN1 2163/4885PTPN5 1903/4885
US-10766888-B1 HMOX1 inducers HMOX1, HMOX2, HMBS FBP1 212/4885PTPN1 3912/4885PTPN5 4185/4885
US-20060194859-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity FABP4, GPR119, LIPC FBP1 1708/4885PTPN1 2163/4885PTPN5 1903/4885
US-20090270468-A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity FABP4, GPR119, LIPC FBP1 1708/4885PTPN1 2163/4885PTPN5 1903/4885
US-20240409533-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS FBP1 212/4885PTPN1 3912/4885PTPN5 4185/4885
US-12071433-B2 HMOX1 inducers HMOX1, HMOX2, HMBS FBP1 249/4885PTPN1 3780/4885PTPN5 4146/4885
US-20240051952-A1 HMOX1 INDUCERS HMOX1, HMOX2, QSOX1 FBP1 552/4885PTPN1 3333/4885PTPN5 3838/4885
US-20090197795-A1 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY FABP4, GPR119, LIPC FBP1 1708/4885PTPN1 2163/4885PTPN5 1903/4885
US-20220177460-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS FBP1 249/4885PTPN1 3780/4885PTPN5 4146/4885
US-20090253762-A1 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY FABP4, GPR119, LIPC FBP1 1708/4885PTPN1 2163/4885PTPN5 1903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.